Diabetic Biomarkers Concordance Compared in South African Blacks
By LabMedica International staff writers Posted on 28 Jun 2021 |

Image: The D-10 Hemoglobin Testing System provides comprehensive, automated hemoglobin testing in a compact footprint, combining HbA1c and HbA2/F/A1c testing on a single platform (Photo courtesy of Bio-Rad)
Sub-Saharan Africa is projected to experience a significant increase in the prevalence of diabetes mellitus by in the near future and accurate, comparable prevalence estimates will be essential to planning and monitoring by public health authorities.
Diagnosis based on glycated hemoglobin (HbA1c) is attractive because it provides an integrated assessment of glycemic status over the preceding three months and has low analytical variability, but the extent to which this single threshold may be adopted in all sub-Saharan African populations is questionable. Existing data suggest that in individuals of African descent, HbA1c may be higher for any given degree of glycaemia than in individuals of European descent.
A large international team of medical scientists led by those at the University of the Witwatersrand (Johannesburg, South Africa) included in a study 765 black individuals aged 40–70 years and with no history of diabetes. The team investigated concordance between hemoglobin A1c (HbA1c)-defined diabetes and fasting plasma glucose (FPG)-defined diabetes in a black South African population with a high prevalence of obesity.
Capillary blood samples were tested for hemoglobin at point of collection using the Haemocue Hb 201+analyser (Haemocue, Ängelholm, Sweden). Whole blood was analyzed for HbA1c using high-performance liquid chromatography on the Bio-Rad D-10 (Bio-Rad Laboratories, Hercules, CA, USA) with a reportable range of 3.8%–18.5%. Plasma was analyzed for glucose using colorimetric methods on the Randox Plus clinical chemistry analyzer (Randox, Crumlin, UK) with a range of 0.36–35 mmol/L. Serum insulin assays were performed on the Immulite 1000 chemistry analysis system (Siemens Healthineers, Erlangen, Germany), using a solid-phase, enzyme-labeled chemiluminescent immunometric assay (range 2–300 μIU/mL).
The investigators reported that the prevalence of HbA1c-defined diabetes was four times the prevalence of FPG-defined diabetes (17.5% versus 4.2%). Classification was discordant in 15.7% of participants, with 111 individuals (14.5%) having HbA1c-only diabetes. Median body mass index, waist and hip circumference, waist-to-hip ratio, subcutaneous adipose tissue and Homoeostatic Model Assessment of Insulin Resistance (HOMA-IR) in participants with HbA1c-only diabetes were similar to those in participants who were normoglycemic by both biomarkers and significantly lower than in participants with diabetes by both biomarkers. HOMA-IR and fat distribution explained additional HbA1c variance beyond glucose and age only in women.
The authors concluded that concordance was poor between HbA1c and FPG in diagnosis of diabetes in black South Africans, and participants with HbA1c-only diabetes phenotypically resembled normoglycemic participants. Further work is necessary to determine which of these parameters better predicts diabetes-related morbidities in this population and whether a population-specific HbA1c threshold is necessary. The study was published on June 17, 2021 in the journal BMJ OPEN.
Related Links:
University of the Witwatersrand
Haemocue
Bio-Rad Laboratories
Randox
Siemens Healthineers
Diagnosis based on glycated hemoglobin (HbA1c) is attractive because it provides an integrated assessment of glycemic status over the preceding three months and has low analytical variability, but the extent to which this single threshold may be adopted in all sub-Saharan African populations is questionable. Existing data suggest that in individuals of African descent, HbA1c may be higher for any given degree of glycaemia than in individuals of European descent.
A large international team of medical scientists led by those at the University of the Witwatersrand (Johannesburg, South Africa) included in a study 765 black individuals aged 40–70 years and with no history of diabetes. The team investigated concordance between hemoglobin A1c (HbA1c)-defined diabetes and fasting plasma glucose (FPG)-defined diabetes in a black South African population with a high prevalence of obesity.
Capillary blood samples were tested for hemoglobin at point of collection using the Haemocue Hb 201+analyser (Haemocue, Ängelholm, Sweden). Whole blood was analyzed for HbA1c using high-performance liquid chromatography on the Bio-Rad D-10 (Bio-Rad Laboratories, Hercules, CA, USA) with a reportable range of 3.8%–18.5%. Plasma was analyzed for glucose using colorimetric methods on the Randox Plus clinical chemistry analyzer (Randox, Crumlin, UK) with a range of 0.36–35 mmol/L. Serum insulin assays were performed on the Immulite 1000 chemistry analysis system (Siemens Healthineers, Erlangen, Germany), using a solid-phase, enzyme-labeled chemiluminescent immunometric assay (range 2–300 μIU/mL).
The investigators reported that the prevalence of HbA1c-defined diabetes was four times the prevalence of FPG-defined diabetes (17.5% versus 4.2%). Classification was discordant in 15.7% of participants, with 111 individuals (14.5%) having HbA1c-only diabetes. Median body mass index, waist and hip circumference, waist-to-hip ratio, subcutaneous adipose tissue and Homoeostatic Model Assessment of Insulin Resistance (HOMA-IR) in participants with HbA1c-only diabetes were similar to those in participants who were normoglycemic by both biomarkers and significantly lower than in participants with diabetes by both biomarkers. HOMA-IR and fat distribution explained additional HbA1c variance beyond glucose and age only in women.
The authors concluded that concordance was poor between HbA1c and FPG in diagnosis of diabetes in black South Africans, and participants with HbA1c-only diabetes phenotypically resembled normoglycemic participants. Further work is necessary to determine which of these parameters better predicts diabetes-related morbidities in this population and whether a population-specific HbA1c threshold is necessary. The study was published on June 17, 2021 in the journal BMJ OPEN.
Related Links:
University of the Witwatersrand
Haemocue
Bio-Rad Laboratories
Randox
Siemens Healthineers
Latest Clinical Chem. News
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
Channels
Molecular Diagnostics
view channel
Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
A tumor marker is a substance found in the body that may signal the presence of cancer. These substances, which can include proteins, genes, molecules, or other biological compounds, are either produced... Read more
Urine Test Diagnoses Early-Stage Prostate Cancer
Prostate cancer is one of the leading causes of death among men worldwide. A major challenge in diagnosing the disease is the absence of reliable biomarkers that can detect early-stage tumors.... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more